No Data
No Data
BeiGene Says New Phase 3 Brukinsa Data Show 'Promising' Efficacy in Leukemia, Lymphoma
BeiGene (BGNE) said Friday that preliminary data from a phase 3 study of Brukinsa in combination with venetoclax to treat patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma s
BeiGene to Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or TP53 mutation Preliminary data suggest promising efficacy and
BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region
DUBAI, United Arab Emirates--(BUSINESS WIRE)--$BGNE #BeiGene--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclud
BeiGene, Ltd. (NASDAQ:BGNE) Shares Could Be 47% Below Their Intrinsic Value Estimate
Benign Growth For BeiGene, Ltd. (NASDAQ:BGNE) Underpins Its Share Price
BeiGene, Ltd.'s (NASDAQ:BGNE) price-to-sales (or "P/S") ratio of 6.4x might make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies
HK stock market anomaly | Beigene (06160) rose nearly 8% in early trading. Beigene's Her2 bispecific antibody has received market approval application acceptance.
Beigene (06160) rose nearly 8% in early trading. As of press time, it rose 6.73%, closing at HKD 99.05 with a turnover of HKD 94.1153 million.